What should be done...

Discussion in 'Alkermes' started by anonymous, May 4, 2019 at 4:26 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I bet you do Andrew K
     

  2. anonymous

    anonymous Guest

    it’s quite amazing that Management hasn’t figured out that the FRM position is both not needed and useless. They contribute absolutely nothing to the sales force and in fact are quite a hindrance. It needs to be eliminated and the money spent on them reallocated towards a better project. No one in the sales force respects the FRM position. Wake up managent.
     
  3. anonymous

    anonymous Guest

    AK is fine... he’s spending his time with his Patriots Blog
     
  4. anonymous

    anonymous Guest

    Want to hit our number? Get rid of deadwood like the FRM position. It is useless and brings no value.
     
  5. anonymous

    anonymous Guest

    Not only is it a useless position, they get paid like a DBL, as do KAM’s. Colossal waste of resources.
     
  6. anonymous

    anonymous Guest

     
  7. anonymous

    anonymous Guest

    Find experienced VP’s to lead brand marketing. Who is worse EK or JB? First vote for the unprofessional dictator EK.
     
  8. anonymous

    anonymous Guest

    Not true. DBLs have much higher target bonuses and upside. But regardless, even if the FRMs and KAMs don't add value, how would getting rid of them make us more likely to hit sales goals? That doesn't make any sense. You can argue they are not a good use of spend but RP (and Wall St) are focused on top line net sales growth.
     
  9. anonymous

    anonymous Guest

    FRMs and KAMs are here to stay. Get on board or get out.
     
  10. anonymous

    anonymous Guest

    KAMs will stay. FRM will be a short lived experiment. Over paid and no real need. They cannot do anything a good TBM can do.
     
  11. anonymous

    anonymous Guest

    The deadwood are TBMs floating around not selling but marred in access and reimbursement issues. Why don’t you spend your time speaking with providers and prescribers? You call on pharmacies, office staff, and other nonclinical folks and assist them with issues violating compliance with impunity. Point the finger elsewhere, it’s not like your numbers or market share are anything to write home about.
     
  12. anonymous

    anonymous Guest

    FRMs have to follow the exact same HIPPA Guidelines as the TBMs. So what is your point?
     
  13. anonymous

    anonymous Guest


    Wow, you really have a lot to learn
     
  14. anonymous

    anonymous Guest

    Not really. That’s the real problem. TBM’s have gotten so comfortable addressing access and reimbursement, there is no actual selling of Vivitrol. There is no one pushing providers to think why Vivitrol instead of alternatives. All calls end up being with nonessential staff.

    TBMs would struggle if they actually had to go into a job selling medication again. Try selling Aristada. See how that works for you.
     
  15. anonymous

    anonymous Guest

    FACTS right there.
     
  16. anonymous

    anonymous Guest

    KAMs are needed, FRMs are masters at pretending to look busy. PM as an example
     
  17. anonymous

    anonymous Guest

    Aristada is hard to sell because it sucks. Vivitrol has been growing quite nicely for a while now.

    If you think vivitrol is sold by “pushing” doctors, you clearly have no idea how to sell It. Especially if you think you could “push a provider” to use vivitrol instead of “alternatives,” I.e., methadone and Suboxone...you are clueless about the marketplace.
     
  18. anonymous

    anonymous Guest

    if you can’t “push” a provider to change their prescribing behaviors in a competitive marketplace then you clearly don’t know what having a sales job is all about. Your excuses are indicative someone who adds no value beyond visiting offices and dropping off lunch and giving samples for no reason.
     
  19. anonymous

    anonymous Guest

    This is part of the reason why FRM’s aren’t being embraced...besides adding little value, show ZERO understanding of the addiction world. I’m not going to explain the nuances of the bupenorphrine world, bup waivered physicians, and their massive lobby, or why it’s, with a few exceptions, a totally different space than we operate in. There’s a reason Vivitrol has grown and continues to grow. We know what we re doing.

    “Samples droppers” “doing lunches/caterer,” etc blasts aren’t sick burns here like on Glaxo’s board (I assume that’s where you came from because most FRM’s did) because this isnt big pharma nor does addiction function like it.

    Every tbm gets plenty of prescribers on board with vivitrol and prescribers to increase prescribing it. At least a good portion of them. It’s why the brand keeps growing.

    I get that this is an anonymous board pretty much known for shit talking, but here’s a piece of serious advice: if the above is actually what you think the issue is, don’t ever say that in front of anyone, because it makes you look like a dumbass.

    If you want the FRM role to have any longevity, you need Tbm’s, dbl’s and rd’s to vouch for the value of it. Saying stupid shit that shows no grasp of the addiction marketplace and doesn’t even apply only makes tbms, dbls, And Rd’s question frm’s competence and ability even more. You’re making it harder for the frm s that do get it and are honest about the struggle to add value but are trying to.
     
  20. anonymous

    anonymous Guest

    So basically your argument is the TBM is a FRM therefore FRM isn’t needed. Here’s a great idea Alkermes, concert all FRM’s and TBM’s into just one sales group and make the geographies smaller.